|drug3199||Standard of care Wiki||0.19|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19. An anticipated total of 132 participants will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally along with the standard of care and the other group with receive the standard of care only but no Dipyridamole ER 200mg/ Aspirin 25mg. Participants will be screened, enrolled, receive treatment, and followed for 28 days. The clinical and laboratory outcomes of all the participants enrolled in the study will be evaluated at the end of the study to explore if there is any difference in the outcomes between 2 groups.
Description: Change in composite COVID ordinal scale at day 15. Ordinal scale: 1) not hospitalized with resumption of normal activities; 2) not hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring oxygen; 4) hospitalized, requiring oxygen; 5) hospitalized, requiring high-flow oxygen therapy, or noninvasive ventilation; 6) hospitalized, requiring invasive ventilation; 7) ventilation plus additional organ support such as pressors, renal replacement therapy and ECMO and 8) death. COVID Ordinal Scale ranges from 1 to 8, with score 1 on the scale corresponds to an ambulatory patient with minimal symptoms and score 8 on the scale corresponds to death.Measure: Covid (Coronavirus Disease-19) Ordinal Scale Time: 15 days
Description: All-cause mortality assessed on day 15.Measure: Mortality Time: 15 days
Description: All-cause mortality assessed on day 28.Measure: Mortality Time: 28 days
Description: Supplemental Oxygen-free daysMeasure: Supplemental Oxygen Time: 28 days
Description: Invasive-ventilator-free daysMeasure: Invasive-ventilator Time: 28 days
Description: ICU-free daysMeasure: ICU stay Time: 28 days
Description: Hospital-free daysMeasure: Hospital stay Time: 28 days
Description: Decrease in the markers D-dimer/ Ferritin/ C-reactive proteinMeasure: Inflammatory markers Time: 15 days
Description: Thromboembolic complications including strokeMeasure: Thromboembolic complications Time: 28 days
Description: COVID ordinal scaleMeasure: COVID ordinal scale Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports